Fresita Proteins Ltd (519242)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Fresita Proteins' revenue was ₹13.0 Cr (+18.7% year on year), and net profit ₹1.7 Cr (against a loss a year earlier); the operating margin was -25.2%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹13.0 | +18.7% | — |
| Operating profit | ₹-3.3 | loss widened | to loss |
| Net profit | ₹1.7 | from loss | +141.9% |
| EPS (₹) | 1.85 | from loss | +143.4% |
| Operating margin | -25.2% | — | — |
📢 Recent Corporate Announcements
Sarda Proteins Ltd has scheduled a Board of Directors meeting on Monday, September 7, 2026. The agenda includes approving and fixing the date, time, venue, and notice for the upcoming Annual General Meeting (AGM). The Board will also finalize the book closure dates and appoint a scrutinizer for remote e-voting. This is a routine administrative compliance filing with no immediate operational or financial impact.
- Board meeting scheduled for Monday, September 7, 2026
- Agenda to finalize day, date, time, and mode for the Annual General Meeting (AGM)
- Board to approve dates for closure of Register of Members and Share Transfer Books
- Appointment of a scrutinizer for remote e-voting and e-voting during AGM
Sarda Proteins has approved a significant fundraise through a Rights Issue of equity shares for an amount not exceeding ₹100 crore. This proposed issue size is substantial, representing approximately 116% of the company's reported net worth of ₹86 crore. Simultaneously, the company announced the resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi, effective August 5, 2026. A Rights Issue Committee has been formed to oversee the process, including the filing of the Draft Letter of Offer with SEBI.
- Approved a Rights Issue of equity shares for a total amount not exceeding ₹100 crore
- Proposed fundraise of ₹100 crore exceeds the company's current net worth of ₹86 crore
- Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
- Board meeting concluded within 45 minutes (4:30 PM to 5:15 PM) to approve these measures
- Company to separately intimate the Record Date upon finalization of the Draft Letter of Offer
Sarda Proteins Ltd has approved a rights issue to raise up to ₹100 crore, a significant amount considering the company's current net worth of ₹86 crore. The board has approved the Draft Letter of Offer (DLOF) to be filed with SEBI and constituted a committee to oversee the process. This capital infusion is massive relative to the company's recent quarterly revenue of ₹0.65 crore (Mar 2026). Additionally, Non-Executive Director Mr. Gunvantray Jayantilal Zaladi resigned effective August 5, 2026.
- Board approved issuance of equity shares on a rights basis for an amount not exceeding ₹100 crore
- Proposed fundraise represents approximately 116% of the company's current net worth of ₹86 crore
- Equity shares to be issued at a face value of ₹10 each
- Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
- Draft Letter of Offer (DLOF) approved for filing with SEBI and stock exchanges
Sarda Proteins has approved a rights issue of up to ₹100 Crore, a massive amount considering the company's current net worth of ₹86 Crore. The Board has approved the Draft Letter of Offer (DLOF) for filing with SEBI and the stock exchanges. This fundraise is highly significant as the company reported a quarterly revenue of only ₹0.65 Crore in March 2026. Additionally, Non-Executive Director Mr. Gunvantray Jayantilal Zaladi has resigned effective August 5, 2026.
- Approved issuance of equity shares on a rights basis for an amount not exceeding ₹10,000 lakhs (₹100 Crore)
- Proposed fundraise of ₹100 Crore is approximately 116% of the company's current net worth of ₹86 Crore
- Quarterly revenue for the period ending March 2026 was reported at ₹0.65 Crore
- Resignation of Non-Executive Director Mr. Gunvantray Jayantilal Zaladi effective August 5, 2026
- Constituted a Rights Issue Committee to oversee the process and finalize the record date
Sarda Proteins Ltd has issued revised audited financial results for FY26 to correct clerical errors involving interest income and the reclassification of share warrants as equity. For the full year ended March 31, 2026, the company reported a total revenue of Rs 16.51 Cr, representing a 31.7% decline from Rs 24.19 Cr in FY25. Despite the revenue drop, net profit improved to Rs 0.45 Cr from a near-break-even Rs 0.005 Cr in the previous year. The Q4 FY26 performance was bolstered by other income of Rs 24.36 Lakhs, leading to a quarterly profit of Rs 0.686 Cr.
- Total Revenue for FY26 declined to Rs 16.51 Cr from Rs 24.19 Cr in FY25.
- Net Profit for FY26 stood at Rs 45.44 Lakhs compared to Rs 0.50 Lakhs in FY25.
- Paid-up Equity Share Capital increased significantly to Rs 89.76 Lakhs from Rs 17.26 Lakhs due to warrant reclassification.
- Q4 FY26 Revenue from operations was minimal at Rs 0.65 Cr compared to Rs 15.26 Cr in the preceding half-year period.
- The company reported zero finance costs and zero debt as per the provided financial context.
Sarda Proteins has scheduled a Board Meeting for August 05, 2026, to evaluate various fund-raising options. The company is considering multiple instruments including equity shares, convertible bonds, debentures, and warrants. Potential routes for this capital infusion include rights issues, private placements, preferential issues, or Qualified Institutions Placements (QIP). As of the announcement on July 31, 2026, the specific quantum of funds to be raised and the intended use of proceeds remain undisclosed.
- Board meeting scheduled for August 05, 2026, to approve fund raising.
- Multiple instruments under consideration including equity, convertible bonds, and warrants.
- Permissible modes include Rights Issue, Private Placement, and QIP.
- Announcement made on July 31, 2026, following a 32.3% price return over the last 6 months.
Sarda Proteins Ltd has issued a revised outcome for its board meeting held on July 4, 2026. The board approved a proposal to change the company's name from "Sarda Proteins Limited" to a new name, which is currently pending approval from the Central Registration Centre (CRC) and the Ministry of Corporate Affairs. This update was filed on July 22, 2026, to include the agenda item that was omitted from the original disclosure.
- Board meeting held on July 4, 2026, commenced at 3:00 p.m. and concluded at 5:40 p.m.
- Revised outcome filed on July 22, 2026, to rectify an omission in the previous filing.
- Proposed name change requires approval from the Ministry of Corporate Affairs (MCA).
- Consequent alteration of the Memorandum of Association (MoA) and Articles of Association (AoA) approved.
Sarda Proteins has issued an addendum to its July 30, 2026, Extraordinary General Meeting (EGM) notice to include three new resolutions. The company is seeking shareholder approval to appoint M/s A H Mandaliya & Associates as statutory auditors for a five-year term (FY 2026-27 to FY 2030-31) following a casual vacancy. Additionally, the board has proposed the regularization of Ms. Minal Surendra Jain as a Woman Independent Director for a five-year term effective July 15, 2026. These items were finalized during a board meeting held on July 15, 2026.
- EGM scheduled for July 30, 2026, at 11:00 A.M. via Video Conferencing
- Proposed 5-year term for M/s A H Mandaliya & Associates as Statutory Auditors ending March 31, 2031
- Appointment of Ms. Minal Surendra Jain, age 26, as a Woman Independent Director for a 5-year term
- Casual vacancy for auditor was originally addressed by a board resolution dated November 26, 2025
Sarda Proteins reported a sharp turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the year-ago period. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while 'Other Income' saw a massive spike to ₹548.10 Lakhs. Crucially, the company disclosed it now operates solely in the 'Renewable Energy Sector Solar Cell Products' segment, a major shift from its historical edible oil focus. The board also established a new corporate office in Rajkot and appointed an Independent Women Director.
- Net Profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY
- Other Income surged to ₹548.10 Lakhs, contributing significantly to the bottom line
- Business segment officially transitioned to Renewable Energy Sector Solar Cell Products
- Appointment of Ms. Minal Surendra Jain as Independent Women Director for a 5-year term
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue reached ₹1,847.40 Lakhs, significantly aided by ₹548.10 Lakhs in other income. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director for a 5-year term. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products'.
- Reported a Net Profit of ₹165.97 Lakhs in Q1 FY27, reversing a loss of ₹49.34 Lakhs in Q1 FY26.
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs in the corresponding quarter last year.
- Other income surged to ₹548.10 Lakhs, representing nearly 30% of total revenue for the quarter.
- Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
- Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a Net Profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, a sharp recovery from the ₹65 Lakhs reported in the preceding quarter (Q4 FY26). A critical disclosure reveals the company has pivoted its operations to the 'Renewable Energy Sector Solar Cell Products' segment. The board also approved a new corporate office in Rajkot and appointed Ms. Minal Surendra Jain as an Independent Woman Director for a 5-year term.
- Net Profit turned positive at ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26
- Revenue from operations increased 18.6% YoY to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs
- Basic and Diluted EPS improved to ₹1.85 from a negative ₹2.86 in the year-ago period
- Company officially shifted its business segment to Renewable Energy Sector Solar Cell Products
- Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026
Sarda Proteins reported a net profit of ₹165.97 Lakhs for the quarter ended June 30, 2026, marking a significant turnaround from a loss of ₹49.34 Lakhs in the same period last year. Total revenue reached ₹1,847.40 Lakhs, bolstered by a substantial surge in 'Other Income' to ₹548.10 Lakhs. Notably, the company has identified its primary business segment as 'Renewable Energy Sector Solar Cell Products,' indicating a shift from its historical edible oil focus. The board also approved the establishment of a new corporate office in Rajkot, Gujarat, to support its operations.
- Net Profit of ₹165.97 Lakhs in Q1 FY27 compared to a net loss of ₹49.34 Lakhs in Q1 FY26.
- Revenue from operations increased by 18.6% YoY to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs.
- Other Income spiked to ₹548.10 Lakhs, representing nearly 30% of the total revenue for the quarter.
- Earnings Per Share (EPS) improved to ₹1.85 from a negative ₹2.86 in the year-ago quarter.
- Establishment of a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
Sarda Proteins reported a significant turnaround in Q1 FY27, posting a net profit of ₹165.97 Lakhs compared to a loss of ₹49.34 Lakhs in the same quarter last year. Revenue from operations grew 18.6% YoY to ₹1,299.30 Lakhs, while total revenue was further bolstered by a sharp increase in other income to ₹548.10 Lakhs. The company also announced the establishment of a new corporate office in Rajkot, Gujarat, and the appointment of an Independent Women Director. Notably, the company now identifies its primary segment as 'Renewable Energy Sector Solar Cell Products', indicating a shift from its historical edible oil focus.
- Net profit of ₹165.97 Lakhs in Q1 FY27 vs a loss of ₹49.34 Lakhs in Q1 FY26.
- Revenue from operations increased to ₹1,299.30 Lakhs from ₹1,095.46 Lakhs YoY.
- Other income surged to ₹548.10 Lakhs from just ₹0.08 Lakhs in the previous year's quarter.
- Established a new Corporate Office in Rajkot, Gujarat, effective July 15, 2026.
- Appointed Ms. Minal Surendra Jain as an Independent Women Director for a 5-year term.
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
